Today: 21 May 2026
Browse Category

LSE:RB.L 20 January 2026 - 7 March 2026

FTSE 100 reels from worst week in a year as oil shock hits London stocks

FTSE 100 reels from worst week in a year as oil shock hits London stocks

The FTSE 100 dropped 5.7% this week, its sharpest fall since April 2025, as oil surged above $90 a barrel and traders slashed UK rate-cut bets. Energy and defence shares held firm, but airlines and miners tumbled. The FTSE 250 lost 0.8% on Friday. Money markets now see little chance of a March Bank of England cut.
7 March 2026
········
Reckitt Benckiser Shares Sink as 2026 Margin Questions Overshadow Q4 Sales Beat

Reckitt Benckiser Shares Sink as 2026 Margin Questions Overshadow Q4 Sales Beat

Reckitt Benckiser shares fell 5.8% in London on Thursday, the steepest drop in 11 months, after the company declined to provide a 2026 margin target despite beating fourth-quarter sales estimates. Comparable sales rose 5.4% in the quarter, led by 17.2% growth in emerging markets, while Europe dropped 4.5%. The company warned of continued weakness in Europe and lower first-quarter demand for over-the-counter remedies.
6 March 2026
··
Reckitt share price ends week higher — Monday’s 235p special dividend could distort the next open

Reckitt share price ends week higher — Monday’s 235p special dividend could distort the next open

Reckitt shares closed up 1.7% at 6,092p on Friday ahead of a 24-for-25 share consolidation and 235p special dividend, both set for Feb. 2. Shareholders approved the moves with over 99% support. The company disclosed a buyback of 58,785 shares at 5,953.57p each, to be held as treasury stock. The dividend follows the £1.6 billion sale of Reckitt’s Essential Home unit to Advent International.
31 January 2026
··
Reckitt share price edges up as special dividend deadline hits — what to know before Feb. 2

Reckitt share price edges up as special dividend deadline hits — what to know before Feb. 2

Reckitt Benckiser shares rose 0.3% to 6,012 pence in early London trading Friday. Investors face a 6 p.m. London cutoff to qualify for a 235 pence-per-share special dividend, with shares going ex-dividend Monday. The company continued share buybacks, purchasing 58,785 shares Thursday as part of its £1 billion programme. Shareholders approved the special dividend and a related share consolidation earlier this week.
30 January 2026
··

Stock Market Today

  • Scotiabank Shares Showing 32% Undervaluation at C$108 Amid Strong Returns
    May 20, 2026, 10:05 PM EDT. Scotiabank (TSX:BNS) stock has rallied to around C$108.50, delivering a 59.4% return over the past year and nearly 79% over five years highlighting strong performance. Despite this, valuation models suggest substantial remaining upside. Simply Wall St's Excess Returns analysis estimates the bank's intrinsic value at approximately C$160 per share, indicating it is 32.2% undervalued compared to current prices. This model calculates excess returns by comparing the bank's return on equity to its cost of equity, reflecting efficient shareholder profit generation. Investors are closely watching key fundamentals including balance sheet resilience and dividend yield as Scotiabank navigates evolving interest rate environments. The stock's valuation score of 4 out of 6 suggests moderate confidence among analysts that price gains can continue.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop